Dr. Niteesh Choudhry, Associate Professor, Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics in Boston, discusses VBID and how looming questions revealed from this study show the model’s importance as well as its need to be better defined.
Dr. Choudhry explains that a key method to better defining VBID is to conduct similar studies within other specialties to learn about outcomes when the model is applied to diseases such as diabetes, hypertension, and hyperlipidemia.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More